Lung Metastasectomy Improves Survival in Patients Affected by Grade 2 and 3 Chondrosarcoma

Oncol Res Treat. 2020;43(4):134-139. doi: 10.1159/000504854. Epub 2020 Jan 24.

Abstract

Aims: The aim of this retrospective study is to evaluate the role of pulmonary metastasectomy (PM) in patients affected by lung metastasis (LM) of grade 2 and 3 chondrosarcoma (CS).

Patients and methods: The study included 61 patients affected by LM. Patients unfit for PM were treated with chemotherapy and radiotherapy.

Results: The patients' mean age was 51 years, ranging from 17 to 84 years; 44 (66.7%) patients had grade 2 CS, while 17 (25.8%) patients had grade 3 CS. Fifty-one patients presented multiple nodules: 44 of those cases were bilateral LM (72.1%). Twenty-nine (47.5%) patients underwent PM, whereas 32 (52.5%) patients underwent chemotherapy and stereotactic radiotherapy alone. At the final follow-up (average of 83 months, range 13-298), 47 (77.0%) patients had died of the disease. A better post-relapse survival rate was observed in patients who underwent PM (55.1 vs. 13.1% at 5-year follow-up, p < 0.001) and in patients with unilateral LM (60.4 vs. 25.6% at 5-year follow-up, p = 0.016). The number of LM also played a prognostic role.

Conclusions: Until significant improvements in chemotherapy can be made, PM can be a valid option in the attempt to improve post-metastatic survival.

Keywords: Chondrosarcoma; Lung; Metastasis; Sarcoma; Surgical therapy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / mortality
  • Bone Neoplasms / pathology
  • Bone Neoplasms / surgery*
  • Chondrosarcoma / mortality
  • Chondrosarcoma / pathology
  • Chondrosarcoma / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / secondary*
  • Lung Neoplasms / surgery*
  • Male
  • Metastasectomy / statistics & numerical data
  • Middle Aged
  • Neoplasm Grading
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome
  • Young Adult